UroGen Pharma (URGN) Earnings Date & Reports

Key Takeaways

• UroGen Pharma is scheduled to report third quarter 2026 results before the market opens on November 5, 2026.
• Wall Street consensus points to revenue of roughly $90 million, up from $27.5 million in the same quarter last year, as the ZUSDURI launch continues to scale.
• Consensus earnings per share (EPS) is near breakeven at around $0.10, versus a loss of $0.69 per share in the prior-year quarter.
• Investors will focus on ZUSDURI net product revenue, prescriber and account growth, and JELMYTO's progress toward its full-year guidance.
• Key watch items include operating expense discipline and updated commentary on pipeline milestones such as UGN-103.

Earnings Context and Why It Matters

UroGen Pharma (URGN) has become one of the more closely watched names in uro-oncology, driven by the commercial launch of ZUSDURI, the first U.S. Food and Drug Administration-approved medicine for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). The launch has rapidly translated into revenue, lifting total sales from $24.2 million in the second quarter of 2025 to $72.5 million in the second quarter of 2026. With ZUSDURI now roughly two quarters into broad reimbursement following a permanent J-code, the upcoming report offers a critical read on whether adoption momentum can continue while the company still manages meaningful operating losses.

Earnings Expectations

For the third quarter of 2026, analysts expect revenue of approximately $90 million, reflecting continued ZUSDURI growth and steady JELMYTO contributions. Consensus EPS is near breakeven at roughly $0.10, compared with a net loss of $0.69 per share in the same period a year earlier.

These expectations follow a strong second quarter, when total revenue reached $72.5 million and ZUSDURI generated $50.4 million in net product revenue, a 73% sequential increase. JELMYTO, UroGen's treatment for low-grade upper tract urothelial cancer (LG-UTUC), contributed $22.0 million and remains on track toward the company's full-year guidance of $97 million to $101 million.

Management has not issued full-year ZUSDURI revenue guidance, noting the product is still early in its launch. Investors will therefore scrutinize underlying commercial metrics, including activated accounts, unique prescribers, and repeat prescriber rates, along with any commentary on operating expenses and cash runway.

AI Screener

Investors tracking UroGen Pharma and similar earnings catalysts can streamline their research with Tickeron's AI Screener. This AI-powered stock and exchange-traded fund (ETF) discovery tool helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener can help identify trade ideas, trending stocks, breakout candidates, and market opportunities far more efficiently than manual screening. Explore the AI Screener to build a more efficient, data-driven watchlist.

Market Reaction and Investor Sentiment

UroGen shares surged about 16% in the first trading session after its second quarter report, as investors rewarded the faster-than-expected revenue ramp and sharply narrowed losses. Sentiment has since cooled, however, with the stock pulling back from those post-earnings highs. Elevated short interest of roughly 16% of shares outstanding indicates that a meaningful portion of the market remains skeptical of the launch trajectory and the company's path to profitability.

Heading into the third quarter print, sentiment is balanced between optimism over ZUSDURI's growing adoption and caution around several risk factors. Management has already signaled it does not expect the same degree of sequential acceleration seen in the second quarter, citing potential summer seasonality and the gradual pace of urologist adoption. Any shortfall in ZUSDURI revenue or a further increase in operating expense guidance could amplify volatility given the sizable short base.

Forward Outlook and Key Factors to Monitor

Beyond the headline revenue and EPS figures, investors should watch how ZUSDURI adoption is progressing across community urology practices, which represent the bulk of the addressable market. Repeat prescriber rates and the time between patient enrollment and treatment initiation are useful signals of long-term demand quality.

The company's expense trajectory also matters. UroGen raised its full-year 2026 operating expense guidance to a range of $260 million to $270 million to support the launch and pipeline, a reminder that profitability is not yet secured. With roughly $108 million in cash, cash equivalents, and marketable securities as of mid-2026, investors will want reassurance that existing resources remain sufficient to reach profitability.

Finally, the pipeline offers upcoming catalysts. UroGen plans to submit a New Drug Application (NDA) for UGN-103, a next-generation mitomycin formulation, in the second half of 2026, with a potential approval in 2027. The Phase 3 trial of UGN-104 is expected to complete enrollment by the end of 2026, and the investigational next-generation oncolytic virus UGN-501 is advancing toward a Phase 1 study. How these programs progress will shape the company's longer-term growth story beyond ZUSDURI and JELMYTO.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations